HHLR Advisors’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

HHLR Advisors’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,962,076	Closed	-$351M	–	100
2021 Q1	$351M	Hold	2,962,076	–	–	3.47%	8
2020 Q4	$350M	Hold	2,962,076	–	–	2.78%	8
2020 Q3	$329M	Hold	2,962,076	–	–	2.49%	8
2020 Q2	$303M	Buy	2,962,076 +210,876	+8%	+$22.6M	2.77%	10
2020 Q1	$297M	Hold	2,751,200	–	–	4%	9
2019 Q4	$320M	Hold	2,751,200	–	–	3.99%	11
2019 Q3	$315M	Hold	2,751,200	–	–	4.33%	10
2019 Q2	$262M	Hold	2,751,200	–	–	5.86%	5
2019 Q1	$251M	Hold	2,751,200	–	–	6.99%	6
2018 Q4	$209M	Buy	+2,751,200	New	+$202M	8.66%	3

HHLR Advisors's CBPO Position: Q2 2021 in Review

HHLR Advisors sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 2,962,076 shares — an estimated $351M sold.

HHLR Advisors first reported a position in CBPO in Q4 2018 and held it in 10 quarters. The position peaked at $351M in Q1 2021. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.

HHLR Advisors reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
HHLR Advisors sold 2,962,076 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $351M.
HHLR Advisors first reported a position in China Biologic Products Holdings, Inc. in Q4 2018 and held it in 10 quarters.
HHLR Advisors's China Biologic Products Holdings, Inc. position peaked at $351M in Q1 2021.
0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.

Based on HHLR Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.